Coventry University Featured PhD Programmes
University of Leeds Featured PhD Programmes
University of Lincoln Featured PhD Programmes

Transglutaminase 2 (TG2) as a novel cancer biomarker and target for chemotherapy


School of Life Sciences

About the Project

Research Group: Biomedical Research Group
https://www.anglia.ac.uk/science-and-engineering/research/institutes-and-groups/biomedical

Proposed supervisory team:
Dr Peter Coussons (),
https://www.anglia.ac.uk/science-and-technology/about/biomedical-and-forensic-science/our-staff/peter-coussons
Dr Claire Pike (),
https://www.anglia.ac.uk/science-and-technology/about/biomedical-and-forensic-science/our-staff/claire-pike

Theme: Cancer Cell Biology
https://www.anglia.ac.uk/science-and-technology/research/our-research-institutes-and-groups/biomedical-research-group/cancer-cell-biology

Summary of the research project


Transglutaminase 2 is an enzyme that cross-links proteins inside cells and contributes to cellular adhesion in tissues. Our group is interested in its many roles that can tip the balance between cellular proliferation and cell death. Our group’s research projects are currently investigating:

1. Whether the increased presence of TG2 in human breast cancers confers direct effects on survival of breast cancer patients.

2. Whether by reducing the levels of TG2 in cancer cells that have become resistant to anti-cancer drugs we can improve the efficiency of these anti-cancer drugs.

3. Whether natural compounds derived from, e.g., spices and red wine can be used to modulate the levels of TG2 and so modulate the behaviour of breast, kidney, liver and other cancer cells. This research offers the possibility of developing new diagnostic approaches and TG2-based therapies for the treatment of human cancers.

4. New potential roles for cancer cell derived exosomes in chemotherapeutic resistance.

The current work involves a wide range of molecular and biophysical techniques including: immunohistological analysis of transglutaminase 2 in human breast cancer biopsy samples; tissue culture of human cancer cell lines; analysis of TG2 expression in response to drug therapy by cell toxicology assay, membrane purification and analysis, Western blot analysis, confocal microscopy and flow cytometry; RT-PCR analysis of mRNA, SiRNA (silencing) knockdown of mRNA; inductively coupled plasma atomic emission spectroscopy for measurement of cellular uptake of platinum based drugs.

Other specialist biophysical methodologies will be developed as part of these projects – particularly project 4.

Expected outcomes are:

1. Validation of transglutaminase 2 as a biomarker for the progression of tumour progression and patient survival, particularly in breast cancer.

2. Validation of transglutaminase 2 as a drug target in diverse cancers including: liver, breast, prostate and kidney cancers.

Where you’ll study


Cambridge (https://www.anglia.ac.uk/student-life/life-on-campus/cambridge-campus)

Next steps


If you wish to be considered for this project, you will need to apply for our Biomedical Science PhD (https://www.anglia.ac.uk/study/postgraduate/biomedical-science-research). In the section of the application form entitled ’Outline research proposal’, please quote the above title and include a research proposal.

Funding Notes

Details of studentships for which funding is available are selected by a competitive process and are advertised on our jobs website (View Website) as they become available.

Email Now

Insert previous message below for editing? 
You haven’t included a message. Providing a specific message means universities will take your enquiry more seriously and helps them provide the information you need.
Why not add a message here

The information you submit to Anglia Ruskin University ARU will only be used by them or their data partners to deal with your enquiry, according to their privacy notice. For more information on how we use and store your data, please read our privacy statement.

* required field

Your enquiry has been emailed successfully





FindAPhD. Copyright 2005-2020
All rights reserved.